01

March

2023

|

07:fifty nine AM

Europe/Amsterdam

Not intended for U.S. and Uk Media

Summary

Submission to the Ministry of Health and fitness, Labor, and Welfare (MHLW) in Japan for aflibercept eight mg in neovascular (moist) age-associated macular degeneration (nAMD) and diabetic macular edema (DME) is based on good results of period III scientific trials, PULSAR and PHOTON / In both equally trials, aflibercept 8 mg demonstrated unparalleled longevity effects with therapy intervals of up to 16 months, with similar visible acuity as perfectly as swift and resilient fluid regulate to the comparator EyleaTM (aflibercept 2 mg) by way of to week 48 / Protection of aflibercept eight mg was reliable with the basic safety profile of Eylea (aflibercept two mg) / Extended cure intervals with much less injections addresses an vital patient need